223132-37-4

Basic information

• Product Name: inolitazone
• Synonyms: inolitazone;5-[[4-[[6-(4-Amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-thiazolidinedione;Efatutazone;RS5444;Inolitazone (CS-7017)
• CAS NO: 223132-37-4
• Molecular Formula: C₂₇H₂₆N₄O₄S
• Molecular Weight: 502.58
• Mol File: 223132-37-4.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 765.7±60.0 °C(Predicted)
• Appearance: /
• Density: 1.39
• PKA: 6.34±0.50(Predicted)
• CAS DataBase Reference: inolitazone(CAS DataBase Reference)
• NIST Chemistry Reference: inolitazone(223132-37-4)
• EPA Substance Registry System: inolitazone(223132-37-4)

Safety Data

• Hazardous Substances Data: 223132-37-4(Hazardous Substances Data)

Usage

General Description

Inolitazone is a chemical compound that belongs to the thiazolidinedione class of drugs, which are known for their insulin-sensitizing and anti-inflammatory properties. It is a potent and selective agonist of the peroxisome proliferator-activated receptor gamma (PPARγ), a transcription factor that plays a key role in regulating glucose and lipid metabolism. Inolitazone has shown promising potential as a treatment for type 2 diabetes and other metabolic disorders by improving insulin sensitivity, lowering blood sugar levels, reducing inflammation, and promoting weight loss. Additionally, it has demonstrated anti-cancer effects in preclinical studies by inhibiting the growth of cancer cells and inducing their death. Despite these therapeutic benefits, the development of inolitazone as a medication has been hampered by safety concerns, particularly its potential to cause cardiovascular and liver toxicity. Consequently, further research is needed to better understand its efficacy and safety profile before it can be considered for clinical use.

Downstream Products

• 1621144-37-3 rac-5-[(p-{[6-(4-amino-3,5-xylyloxy)-1-methyl-1,3-diaza-1H-inden-2-yl]methoxy}phenyl)methyl]-(5-²H)-1,3-thiazolidine-2,4-dione 

Relevant articles and documents

CRYSTAL OF THIAZOLIDINEDIONE COMPOUND, AND PROCESS FOR PRODUCTION THEREOF

Thiazolidinedione compound crystalline forms useful as a bulk material for the manufacture of a peroxisome proliferator-activated receptor (PPAR) γ activator or an anticancer pharmaceutical composition are provided, which are hydrate crystalline forms of

Amine derivative compounds

An amine compound of the formula (I): wherein R1 represents an optionally substituted carbamoyl group, etc., R2 represents a hydrogen atom, etc., R3 represents a C1-C10 alkyl group etc., W1, W2 and W3 are the same or different and each represent a single bond or a C1-C8 alkylene group, X, Y and Q represent a sulfur atom, etc., Z represents a =CH- group, etc., Ar represents a benzene ring, etc. and L represents a hydrogen atom, etc., or a pharmacologically acceptable salt thereof. These compounds are useful in the treatment and/or prophylaxis of diseases such as diabetes, hyperlipemia, arteriosclerosis, cancer, etc.

AMINE DERIVATIVES

An amine derivative compound of the formula (I):wherein R1 represents an optionally substituted carbamoyl group, etc., R2 represents a hydrogen atom, etc., R3 represents a C1-C10 alkyl group etc., W1, W2 and W3 are the same or different and each represent a single bond or a C1-C8 alkylene group, X, Y and Q represent a sulfur atom, etc., Z represents a =CH- group, etc., Ar represents a benzene ring, etc. and L represents a hydrogen atom, etc. or a pharmacologically acceptable salt thereof is useful as a therapeutic and/or preventing agent for diabetes, hyperlipemia, arteriosclerosis, cancer, etc.